The UCT Clinical Trials Unit, housed within the Desmond Tutu HIV Centre (DTHC) at the University of Cape Town, is committed to the pursuit of excellence in research, treatment, training and prevention of HIV and related infections in Southern Africa
In 2013 the Desmond Tutu HIV Foundation partnered with the Faculty of Health Sciences, Departments of Medicine and Pharmacology at the University of Cape Town to establish an expanded Clinical Trials Unit.
Our CTU model regards training and development as an important function. We invest in our staff through a robust and agile training program that positively impacts performance of our study teams.
Home > Home


Thursday, 14 November 2019
Guidelines fail to address needs of adolescents living with HIV transitioning to adult health care in low- and middle-income countries

Only five of 12 low- and middle-income countries had transition guidelines, according to a systemic review of adolescents living with HIV transitioning from paediatric to adult health care published in AIDS and Behavior.

The authors believe this to be the first review to survey the literature on barriers and facilitators of transition for adolescents living with HIV in low- and middle-income countries and to compare these factors to countries’ current guidelines.

Publication Date:
Fri, 11 Oct 2019 - 22:00
Same day treatment IAS
Same-day initiation of ART feasible and safe without CD4 counts, Thai study shows

Three models of same-day antiretroviral therapy (ART), tested in different hospitals in Thailand, are feasible and safe, researchers report. The models have been implemented in Thailand since 2017, following a World Health Organization recommendation that all individuals diagnosed as HIV positive should receive ART on the same day of diagnosis, if they are ready.

Publication Date:
Fri, 11 Oct 2019 - 21:45
FDA Approves Second Drug to Prevent HIV Infection as Part of Ongoing Efforts to End the HIV Epidemic

The U.S. Food and Drug Administration today approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. Descovy is not indicated in individuals at risk of HIV-1 infection from receptive vaginal sex because the effectivness in this population has not been evaluated.

Publication Date:
Fri, 11 Oct 2019 - 21:30
ADM Giroir
ADM Giroir Discusses Ending the HIV Epidemic: A Plan for America with APHA

ADM Brett Giroir, MD, Assistant Secretary for Health, recently spoke to the American Public Health Association (APHA) about Ending the HIV Epidemic: 

Publication Date:
Fri, 11 Oct 2019 - 21:00